Lilly Tozer A study that followed thousands of people over 25 years has identified proteins linked to the development of dementia if their levels are unbalanced during middle age. The findings, published in Science Translational Medicine on 19 July1, could contribute to the development of new diagnostic tests, or even treatments, for dementia-causing diseases. Most of the proteins have functions unrelated to the brain. “We’re seeing so much involvement of the peripheral biology decades before the typical onset of dementia,” says study author Keenan Walker, a neuroscientist at the US National Institute on Aging in Bethesda, Maryland. Equipped with blood samples from more than 10,000 participants, Walker and his colleagues questioned whether they could find predictors of dementia years before its onset by looking at a person’s proteome — the collection of all the proteins expressed throughout the body. They searched for any signs of dysregulation — when proteins are at levels much higher or lower than normal. The samples were collected as part of an ongoing study that began in 1987. Participants returned for examination six times over three decades, and during this time, around 1 in 5 of them developed dementia. The researchers found 32 proteins that, if dysregulated in people aged 45 to 60, were strongly associated with an elevated chance of developing dementia in later life. It is unclear how exactly these proteins might be involved in the disease, but the link is “highly unlikely to be due to just chance alone”, says Walker © 2023 Springer Nature Limited

Keyword: Alzheimers
Link ID: 28856 - Posted: 07.22.2023

Geneva Abdul The so-called “brain fog” symptom associated with long Covid is comparable to ageing 10 years, researchers have suggested. In a study by King’s College London, researchers investigated the impact of Covid-19 on memory and found cognitive impairment highest in individuals who had tested positive and had more than three months of symptoms. The study, published on Friday in a clinical journal published by The Lancet, also found the symptoms in affected individuals stretched to almost two years since initial infection. “The fact remains that two years on from their first infection, some people don’t feel fully recovered and their lives continue to be impacted by the long-term effects of the coronavirus,” said Claire Steves, a professor of ageing and health at King’s College. “We need more work to understand why this is the case and what can be done to help.” An estimated two million people living in the UK were experiencing self-reported long Covid – symptoms continuing for more than four weeks since infection – as of January 2023, according to the 2023 government census. Commonly reported symptoms included fatigue, difficulty concentrating, shortness of breath and muscle aches. The study included more than 5,100 participants from the Covid Symptom Study Biobank, recruited through a smartphone app. Through 12 cognitive tests measuring speed and accuracy, researchers examined working memory, attention, reasoning and motor controls between two periods of 2021 and 2022. © 2023 Guardian News & Media Limited or

Keyword: Learning & Memory; Attention
Link ID: 28854 - Posted: 07.22.2023

By Pam Belluck Treating Alzheimer’s patients as early as possible — when symptoms and brain pathology are mildest — provides a better chance of slowing cognitive decline, a large study of an experimental Alzheimer’s drug presented Monday suggests. The study of 1,736 patients reported that the drug, donanemab, made by Eli Lilly, can modestly slow the progression of memory and thinking problems in early stages of Alzheimer’s, and that the slowing was greatest for early-stage patients when they had less of a protein that creates tangles in the brain. For people at that earlier stage, donanemab appeared to slow decline in memory and thinking by about four and a half to seven and a half months over an 18-month period compared with those taking a placebo, according to the study, published in the journal JAMA. Among people with less of the protein, called tau, slowing was most pronounced in those younger than 75 and those who did not yet have Alzheimer’s but had a pre-Alzheimer’s condition called mild cognitive impairment, according to data presented Monday at the Alzheimer’s Association International Conference in Amsterdam. “The earlier you can get in there, the more you can impact it before they’ve already declined and they’re on this fast slope,” Dr. Daniel Skovronsky, Eli Lilly’s chief medical and scientific officer, said in an interview. “No matter how you cut the data — earlier, younger, milder, less pathology — every time, it just looks like early diagnosis and early intervention are the key to managing this disease,” he added. The findings and the recent approval of another drug that modestly slows decline in the early stages of Alzheimer’s, Leqembi, signal a potentially promising turn in the long, rocky path toward finding effective medications for Alzheimer’s, a brutal disease that plagues more than six million Americans. Donanemab is currently being considered for approval by the Food and Drug Administration. © 2023 The New York Times Company

Keyword: Alzheimers
Link ID: 28852 - Posted: 07.19.2023

Nicola Davis Science correspondent Taking part in activities such as chess, writing a journal, or educational classes in older age may help to reduce the risk of dementia, a study has suggested. According to the World Health Organization, more than 55 million people have the disease worldwide, most of them older people. However experts have long emphasised that dementia is not an inevitable part of ageing, with being active, eating well and avoiding smoking among the lifestyle choices that can reduce risk. Now researchers have revealed fresh evidence that challenging the brain could also be beneficial. Writing in the journal Jama Network Open, researchers in the US and Australia report how they used data from the Australian Aspree Longitudinal Study of Older Persons covering the period from 1 March 2010 to 30 November 2020. Participants in the study were over the age of 70, did not have a major cognitive impairment or cardiovascular disease when recruited between 2010 and 2014, and were assessed for dementia through regular study visits. In the first year, participants were asked about their social networks. They were also questioned on whether they undertook certain leisure activities or trips out to venues such as galleries or restaurants, and how frequently: never, rarely, sometimes, often or always. The team analysed data from 10,318 participants, taking into account factors such as age, sex, smoking status, education, socioeconomic status, and whether participants had other diseases such as diabetes. The results reveal that for activities such as writing letters or journals, taking educational classes or using a computer, increasing the frequency of participation by one category, for example from “sometimes” to “often”, was associated with an 11% drop in the risk of developing dementia over a 10-year period. Similarly, increased frequency of activities such as card games, chess or puzzle-solving was associated with a 9% reduction in dementia risk. © 2023 Guardian News & Media Limited

Keyword: Alzheimers; Learning & Memory
Link ID: 28851 - Posted: 07.19.2023

Lilly Tozer Injecting ageing monkeys with a ‘longevity factor’ protein can improve their cognitive function, a study reveals. The findings, published on 3 July in Nature Aging1, could lead to new treatments for neurodegenerative diseases. It is the first time that restoring levels of klotho — a naturally occurring protein that declines in our bodies with age — has been shown to improve cognition in a primate. Previous research on mice had shown that injections of klotho can extend the animals’ lives and increases synaptic plasticity2 — the capacity to control communication between neurons, at junctions called synapses. “Given the close genetic and physiological parallels between primates and humans, this could suggest potential applications for treating human cognitive disorders,” says Marc Busche, a neurologist at the UK Dementia Research Institute group at University College London. The protein is named after the Greek goddess Clotho, one of the Fates, who spins the thread of life. The study involved testing the cognitive abilities of old rhesus macaques (Macaca mulatta), aged around 22 years on average, before and after a single injection of klotho. To do this, researchers used a behavioural experiment to test for spatial memory: the monkeys had to remember the location of an edible treat, placed in one of several wells by the investigator, after it was hidden from them. Study co-author Dena Dubal, a physician-researcher at the University of California, San Francisco, compares the test to recalling where you left your car in a car park, or remembering a sequence of numbers a couple of minutes after hearing it. Such tasks become harder with age. The monkeys performed significantly better in these tests after receiving klotho — before the injections they identified the correct wells around 45% of the time, compared with around 60% of the time after injection. The improvement was sustained for at least two weeks. Unlike in previous studies involving mice, relatively low doses of klotho were effective. This adds an element of complexity to the findings, which suggests a more nuanced mode of actions than was previously thought, Busche says. © 2023 Springer Nature Limited

Keyword: Learning & Memory; Development of the Brain
Link ID: 28847 - Posted: 07.06.2023

By Tammy Worth In two decades as a pediatrician, Jason Reynolds has had no success treating patients with opioid use disorder by sending them to rehab. But five years ago, when his Massachusetts practice, Wareham Pediatric Associates PC, became the first in the state to offer medication therapy to adolescent patients, he saw dramatic results. The first patient he treated with medication, a young man named Nate, had overdosed on opioids twice in the 24-hour period before seeing Reynolds. But that patient has had no opioid relapses since starting drug therapy. Reynolds’ success received a lot of media attention, and one interviewer, he recalls, asked Nate if any of his friends would also consider starting the treatment. Reynolds is among a small minority of pediatricians using medication to treat opioid use disorder in adolescents. Fewer than 2 percent of all physicians prescribing the medications are pediatricians, and many youth rehabilitation facilities don’t offer them at all. Medication for opioid use disorder (MOUD) uses buprenorphine or methadone to reduce cravings and withdrawal symptoms, or naltrexone to block the high that users would otherwise get if they decided to use opioids. Though MOUD is often used to treat adults, several barriers have prevented it from being adopted more widely for youth. Reynolds and a handful of other practitioners across the country are now working to provide education and training to other health care providers, hoping to increase use of this life-saving treatment. Opioid use among US youth is on the rise nationally, with diagnoses increasing from 0.26 per 100,000 person-years in 2001 to 1.51 in 2014. Overdose deaths have also spiked, more than doubling among youth ages 14 to 18, from 492 in 2019 to 1,146 in 2021. © 2023 Annual Reviews

Keyword: Drug Abuse; Development of the Brain
Link ID: 28844 - Posted: 07.06.2023

By Claudia Lopez Lloreda There are plenty of reasons to get off your duff and exercise—but is improving your brain one of them? The U.S. Centers for Disease Control and Prevention touts exercise as a way to “boost brain health,” while the World Health Organization suggests that about 2 hours of moderate activity or 75 minutes of vigorous activity per week can help improve thinking and memory skills. But new research reveals a more complex picture. One recent review of the literature suggests the studies tying exercise to brain health may have important limitations, including small sample sizes. Other studies suggest there is no one-size-fits-all approach to exercising as a way to boost cognition or prevent age-related cognitive decline. Still others indicate exercise may actually be harmful in people with certain medical conditions. Here’s the latest on what we know. What is the science linking exercise and improved brain function? Many studies correlate participants’ self-reported exercise with scores on cognitive tests, or track the effects of randomizing participants into groups that either exercise or remain sedentary. They typically find that the more physical activity a person does, the better their cognition. This result holds for healthy people, stroke survivors, and those with other neurological conditions such as Alzheimer’s disease. A study published earlier this year relied on genetic data to explore the effects of exercise. A team led by sports scientist Boris Cheval at the University of Geneva grouped about 350,000 people in the United Kingdom according to genetic variants associated with more or less physical activity. Those with an apparent genetic predisposition to be more active also tended to perform better on a set of cognitive tests, the researchers concluded in Scientific Reports. Other studies have focused on age-related cognitive decline. Research published in February in the Journal of Neurology, Neurosurgery & Psychiatry tracked more than 1400 people for 30 years, showing that more physical activity was associated with better cognitive performance at age 69.

Keyword: Development of the Brain; Alzheimers
Link ID: 28838 - Posted: 07.01.2023

Nicola Davis Taking a short nap during the day may help to protect the brain’s health as it ages, researchers have suggested after finding that the practice appears to be associated with larger brain volume. While previous research has suggested long naps could be an early symptom of Alzheimer’s disease, other work has revealed that a brief doze can improve people’s ability to learn. Now researchers say they have found evidence to suggest napping may help to protect against brain shrinkage. That is of interest, the team say, as brain shrinkage, a process that occurs with age, is accelerated in people with cognitive problems and neurodegenerative diseases, with some research suggesting this may be related to sleep problems. “In line with these studies, we found an association between habitual daytime napping and larger total brain volume, which could suggest that napping regularly provides some protection against neurodegeneration through compensating for poor sleep,” the researchers note. Writing in the journal Sleep Health, researchers at UCL and the University of the Republic in Uruguay report how they drew on data from the UK Biobank study that has collated genetic, lifestyle and health information from 500,000 people aged 40 to 69 at recruitment. The team used data from 35,080 Biobank participants to look at whether a combination of genetic variants that have previously been associated with self-reported habitual daytime napping are also linked to brain volume, cognition and other aspects of brain health. © 2023 Guardian News & Media Limited

Keyword: Sleep; Development of the Brain
Link ID: 28829 - Posted: 06.21.2023

By Harrison Smith As a young boy in small-town Mississippi, Donald Triplett was oddly distant, with no apparent interest in his parents or anyone else who tried to make conversation. He was obsessed with spinning round objects and had an unusual way of speaking, substituting “you” for “I” and repeating words like “business” and “chrysanthemum.” He also showed a savant-like brilliance, naming notes as they were played on the piano and performing mental calculations with ease. When a visitor asked “87 times 23,” he didn’t hesitate before answering — correctly — “2,001.” Mr. Triplett would make medical history as “Case 1,” the first person formally diagnosed with autism. His upbringing and behavior were described at length in a 1943 scientific article by Austrian American psychiatrist Leo Kanner, “Autistic Disturbances of Affective Contact,” which outlined the developmental disability now known as autism spectrum disorder, or ASD. The article went on to describe 10 other autistic children, most of whom were locked away in state schools and hospitals while experiencing communication and behavior challenges. Checking in with his former subjects almost 30 years later, Kanner would write that institutionalization was “tantamount to a life sentence … a total retreat to near-nothingness.” Mr. Triplett, by contrast, gained acceptance and admiration while remaining a part of his community. With support from his family, which could afford to send him to Kanner and which later set up a trust fund to look after him, he graduated from college, got a job as a bank teller and found companionship in a morning coffee club at City Hall. He played golf, sang in a choir and traveled the world, visiting at least three-dozen countries and making it to Hawaii 17 times. By choice, he traveled alone, surprising relatives when he would announce at Sunday dinner that he had recently returned from seeing a golf tournament in California or, in search of an oyster dinner, driven his Cadillac to New Orleans.

Keyword: Autism
Link ID: 28826 - Posted: 06.21.2023

By Claudia Lopez Lloreda A baby born through the vaginal canal picks up critical microbes along the way that help it stay healthy later in life. But babies delivered via cesarean section miss out on those useful, gut-colonizing bacteria, which may put them at greater risk of developing certain health conditions and developmental disorders. Now, researchers at Southern Medical University say that by exposing C-section babies to the microbes they’ve missed—an intervention called vaginal seeding—doctors can partially restore these missing gut bacteria. The procedure may even aid in their early development. Newborns delivered via C-section who received their mother’s vaginal microbes had more advanced motor and communication skills than other C-section babies months later, the team reports today in Cell Host & Microbe. But some clinicians argue these benefits for infants have not yet been proved, nor has the procedure’s safety. “This study establishes a link showing that there is a possible benefit in a select group of infants and mothers,” says Mehreen Zaigham, an obstetrician at Lund University who was not involved in the study. “But it has to be proven with larger longitudinal studies.” The microbiomes of C-section babies look a lot different from those of babies born vaginally. In particular, they have lower numbers of Lactobacillus, Escherichia, and Bacteroides bacteria in their guts. These microbes are believed to be critical for growth and are thought to help protect against asthma, allergies, obesity, and autoimmune disorders—all conditions that are more common among C-section babies. A few highly controversial studies have suggested some babies delivered by C-section may be at a greater risk of developing neurodevelopmental conditions such as autism spectrum disorder, which some researchers attribute to their disrupted microbiome. Other researchers have roundly criticized that suggestion, however. To restore the microbiomes of infants delivered by C-section, researchers have come up with a simple solution: Swab them with bacteria from their mother’s vagina shortly after they are born. This method, called vaginal seeding, was first clinically tested 7 years ago by Jose Clemente, a geneticist at the Icahn School of Medicine at Mount Sinai, and Maria Gloria Dominguez Bello, a microbial ecologist at Rutgers University, who found the procedure indeed restored microbes that C-section babies lacked. However, these results were based on a small group of just 11 babies.

Keyword: Development of the Brain; Neuroimmunology
Link ID: 28824 - Posted: 06.17.2023

Kerri Smith In a dimly lit laboratory in London, a brown mouse explores a circular tabletop, sniffing as it ambles about. Suddenly, silently, a shadow appears. In a split second, the mouse’s brain whirs with activity. Neurons in its midbrain start to fire, sensing the threat of a potential predator, and a cascade of activity in an adjacent region orders its body to choose a response — freeze to the spot in the hope of going undetected, or run for shelter, in this case a red acetate box stationed nearby. From the mouse’s perspective, this is life or death. But the shadow wasn’t cast by a predator. Instead, it is the work of neuroscientists in Tiago Branco’s lab, who have rigged up a plastic disc on a lever to provoke, and thereby study, the mouse’s escape behaviour. This is a rapid decision-making process that draws on sensory information, previous experience and instinct. Branco, a neuroscientist at the Sainsbury Wellcome Centre at University College London, has wondered about installing a taxidermied owl on a zip wire to create a more realistic experience. And his colleagues have more ideas — cutting the disc into a wingspan shape, for instance. “Having drones — that would also be very nice,” says Dario Campagner, a researcher in Branco’s lab. A mouse detects a looming threat and runs for cover. The shadow has been darkened. The set-up is part of a growing movement to step away from some of the lab experiments that neuroscientists have used for decades to understand the brain and behaviour. Such exercises — training an animal to use a lever or joystick to get a reward, for example, or watching it swim through a water maze — have established important principles of brain activity and organization. But they take days to months of training an animal to complete specific, idiosyncratic tasks. The end result, Branco says, is like studying a “professional athlete”; the brain might work differently in the messy, unpredictable real world. Mice didn’t evolve to operate a joystick. Meanwhile, many behaviours that come naturally — such as escaping a predator, or finding scarce food or a receptive mate — are extremely important for the animal, says Ann Kennedy, a theoretical neuroscientist at Northwestern University in Chicago, Illinois. They are “critical to survival, and under selective pressure”, she says. By studying these natural actions, scientists are hoping to glean lessons about the brain and behaviour that are more holistic and more relevant to everyday activity than ever before.

Keyword: Learning & Memory; Evolution
Link ID: 28822 - Posted: 06.14.2023

By Jordan Kinard Long the fixation of religions, philosophy and literature the world over, the conscious experience of dying has recently received increasingly significant attention from science. This comes as medical advances extend the ability to keep the body alive, steadily prying open a window into the ultimate locked room: the last living moments of a human mind. “Around 1959 humans discovered a method to restart the heart in people who would have died, and we called this CPR,” says Sam Parnia, a critical care physician at NYU Langone Health. Parnia has studied people’s recollections after being revived from cardiac arrest—phenomena that he refers to as “recalled experiences surrounding death.” Before CPR techniques were developed, cardiac arrest was basically synonymous with death. But now doctors can revive some people up to 20 minutes or more after their heart has stopped beating. Furthermore, Parnia says, many brain cells remain somewhat intact for hours to days postmortem—challenging our notions of a rigid boundary between life and death. Advancements in medical technology and neuroscience, as well as shifts in researchers’ perspectives, are revolutionizing our understanding of the dying process. Research over the past decade has demonstrated a surge in brain activity in human and animal subjects undergoing cardiac arrest. Meanwhile large surveys are documenting the seemingly inexplicable periods of lucidity that hospice workers and grieving families often report witnessing in people with dementia who are dying. Poet Dylan Thomas famously admonished his readers, “Do not go gentle into that good night. Rage, rage against the dying of the light.” But as more resources are devoted to the study of death, it is becoming increasingly clear that dying is not the simple dimming of one’s internal light of awareness but rather an incredibly active process in the brain. © 2023 Scientific American,

Keyword: Attention; Development of the Brain
Link ID: 28820 - Posted: 06.14.2023

Kari Paul and Maanvi Singh Elon Musk’s brain-implant company Neuralink last week received regulatory approval to conduct the first clinical trial of its experimental device in humans. But the billionaire executive’s bombastic promotion of the technology, his leadership record at other companies and animal welfare concerns relating to Neuralink experiments have raised alarm. “I was surprised,” said Laura Cabrera, a neuroethicist at Penn State’s Rock Ethics Institute about the decision by the US Food and Drug Administration to let the company go ahead with clinical trials. Musk’s erratic leadership at Twitter and his “move fast” techie ethos raise questions about Neuralink’s ability to responsibly oversee the development of an invasive medical device capable of reading brain signals, Cabrera argued. “Is he going to see a brain implant device as something that requires not just extra regulation, but also ethical consideration?” she said. “Or will he just treat this like another gadget?” Neuralink is far from the first or only company working on brain interface devices. For decades, research teams around the world have been exploring the use of implants and devices to treat conditions such as paralysis and depression. Already, thousands use neuroprosthetics like cochlear implants for hearing. But the broad scope of capabilities Musk is promising from the Neuralink device have garnered skepticism from experts. Neuralink entered the industry in 2016 and has designed a brain-computer interface (BCI) called the Link – an electrode-laden computer chip that can be sewn into the surface of the brain and connects it to external electronics – as well as a robotic device that implants the chip. © 2023 Guardian News & Media Limited

Keyword: Robotics; Learning & Memory
Link ID: 28816 - Posted: 06.07.2023

By Kate Laskowski In the age-old debate about nature versus nurture — whether our characteristics are forged by our genes or our upbringing — I have an answer for you. It is both. And it is neither. I’m a behavioral ecologist who seeks to answer this question by studying a particular kind of fish. The Amazon molly (Poecilia formosa) is an experimental goldmine for these types of questions. She naturally clones herself by giving birth to offspring with identical genomes to her own and to each other’s. A second quirk of this little fish is that her offspring are born live and are completely independent from birth. This means I can control their experiences from the earliest possible age. Essentially, this fish gives me and my colleagues the opportunity to perform “twin studies” to understand how and why individuality develops. And what we’ve found may surprise you. As humans, we know the critical importance of our personalities. These persistent differences among us shape how we navigate our worlds and respond to major life events; whether we are bold or shy; whether we ask someone on a second date or not. Given the obvious importance of personality, it’s perhaps a bit surprising that scientists generally overlooked these kinds of differences in other species for a long time. Up until about 30 years ago, these differences (what I prefer to call “individuality,” as it avoids the human connotation of “personality”) were typically viewed as cute anecdotes with little evolutionary importance. Instead, researchers focused on the typical behavior of a given population. With guppies, for example — a classic workhorse of behavioral ecology research — researchers found that fish will, on average, swim more tightly together if they live among lots of predatory fish, whereas fish from areas with fewer predators spend less time schooling and more time fighting one another, as they don’t have to worry so much about being eaten. © 2023 Annual Reviews

Keyword: Development of the Brain; Genes & Behavior
Link ID: 28815 - Posted: 06.07.2023

Sara Reardon Vaccination against shingles might also prevent dementia, such as that caused by Alzheimer’s disease, according to a study of health records from around 300,000 people in Wales. The analysis found that getting the vaccine lowers the risk of dementia by 20%. But some puzzling aspects of the analysis have stirred debate about the work’s robustness. The study was published on the medRxiv preprint server on 25 May and has not yet been peer reviewed. “If it is true, it’s huge,” says Alberto Ascherio, an epidemiologist at Harvard University in Cambridge, Massachusetts, who was not involved in the study. “Even a modest reduction in risk is a tremendous impact.” Dementia–infection link The idea that viral infection can play a part in at least some dementia cases dates back to the 1990s, when biophysicist Ruth Itzhaki at the University of Manchester, UK, and her colleagues found herpesviruses in the brains of deceased people with dementia2. The theory has been controversial among Alzheimer’s researchers. But recent work has suggested that people infected with viruses that affect the brain have higher rates of neurodegenerative diseases3. Research has also suggested that those vaccinated against certain viral diseases are less likely to develop dementia4. But all these epidemiological studies have shared a key problem: people who get any type of vaccination tend to have healthier lifestyles than those who don’t5, meaning that other factors could account for their lowered risk of diseases such as Alzheimer’s. With that in mind, epidemiologist Pascal Geldsetzer at Stanford University in California and his colleagues turned to a natural experiment: a shingles vaccination programme in Wales, which began on 1 September 2013. Shingles is caused by the reawakening of inactive varicella zoster virus (VZV), the herpesvirus that causes chickenpox and which is present in most people. Shingles is most common in older adults and can cause severe pain and rashes. © 2023 Springer Nature Limited

Keyword: Alzheimers; Neuroimmunology
Link ID: 28814 - Posted: 06.07.2023

Davide Castelvecchi The wrinkles that give the human brain its familiar walnut-like appearance have a large effect on brain activity, in much the same way that the shape of a bell determines the quality of its sound, a study suggests1. The findings run counter to a commonly held theory about which aspect of brain anatomy drives function. The study’s authors compared the influence of two components of the brain’s physical structure: the outer folds of the cerebral cortex — the area where most higher-level brain activity occurs — and the connectome, the web of nerves that links distinct regions of the cerebral cortex. The team found that the shape of the outer surface was a better predictor of brainwave data than was the connectome, contrary to the paradigm that the connectome has the dominant role in driving brain activity. “We use concepts from physics and engineering to study how anatomy determines function,” says study co-author James Pang, a physicist at Monash University in Melbourne, Australia. The results were published in Nature on 31 May1. ‘Exciting’ a neuron makes it fire, which sends a message zipping to other neurons. Excited neurons in the cerebral cortex can communicate their state of excitation to their immediate neighbours on the surface. But each neuron also has a long filament called an axon that connects it to a faraway region within or beyond the cortex, allowing neurons to send excitatory messages to distant brain cells. In the past two decades, neuroscientists have painstakingly mapped this web of connections — the connectome — in a raft of organisms, including humans. The authors wanted to understand how brain activity is affected by each of the ways in which neuronal excitation can spread: across the brain’s surface or through distant interconnections. To do so, the researchers — who have backgrounds in physics and neuroscience — tapped into the mathematical theory of waves.

Keyword: Brain imaging; Development of the Brain
Link ID: 28811 - Posted: 06.03.2023

by Adam Kirsch Giraffes will eat courgettes if they have to, but they really prefer carrots. A team of researchers from Spain and Germany recently took advantage of this preference to investigate whether the animals are capable of statistical reasoning. In the experiment, a giraffe was shown two transparent containers holding a mixture of carrot and courgette slices. One container held mostly carrots, the other mostly courgettes. A researcher then took one slice from each container and offered them to the giraffe with closed hands, so it couldn’t see which vegetable had been selected. In repeated trials, the four test giraffes reliably chose the hand that had reached into the container with more carrots, showing they understood that the more carrots were in the container, the more likely it was that a carrot had been picked. Monkeys have passed similar tests, and human babies can do it at 12 months old. But giraffes’ brains are much smaller than primates’ relative to body size, so it was notable to see how well they grasped the concept. Such discoveries are becoming less surprising every year, however, as a flood of new research overturns longstanding assumptions about what animal minds are and aren’t capable of. A recent wave of popular books on animal cognition argue that skills long assumed to be humanity’s prerogative, from planning for the future to a sense of fairness, actually exist throughout the animal kingdom – and not just in primates or other mammals, but in birds, octopuses and beyond. In 2018, for instance, a team at the University of Buenos Aires found evidence that zebra finches, whose brains weigh half a gram, have dreams. Monitors attached to the birds’ throats found that when they were asleep, their muscles sometimes moved in exactly the same pattern as when they were singing out loud; in other words, they seemed to be dreaming about singing. © 2023 Guardian News & Media Limited

Keyword: Evolution; Learning & Memory
Link ID: 28808 - Posted: 05.31.2023

Emily Waltz Researchers have been exploring whether zapping a person’s brain with electrical current through electrodes on their scalp can improve cognition.Credit: J.M. Eddin/Military Collection/Alamy After years of debate over whether non-invasively zapping the brain with electrical current can improve a person’s mental functioning, a massive analysis of past studies offers an answer: probably. But some question that conclusion, saying that the analysis spans experiments that are too disparate to offer a solid answer. In the past six years, the number of studies testing the therapeutic effects of a class of techniques called transcranial electrical stimulation has skyrocketed. These therapies deliver a painless, weak electrical current to the brain through electrodes placed externally on the scalp. The goal is to excite, disrupt or synchronize signals in the brain to improve function. Researchers have tested transcranial alternating current stimulation (tACS) and its sister technology, tDCS (transcranial direct current stimulation), on both healthy volunteers and those with neuropsychiatric conditions, such as depression, Parkinson’s disease or addiction. But study results have been conflicting or couldn’t be replicated, leading researchers to question the efficacy of the tools. The authors of the new analysis, led by Robert Reinhart, director of the cognitive and clinical neuroscience laboratory at Boston University in Massachusetts, say they compiled the report to quantify whether tACS shows promise, by comparing more than 100 studies of the technique, which applies an oscillating current to the brain. “We have to address whether or not this technique is actually working, because in the literature, you have a lot of conflicting findings,” says Shrey Grover, a cognitive neuroscientist at Boston University and an author on the paper. © 2023 Springer Nature Limited

Keyword: Learning & Memory
Link ID: 28807 - Posted: 05.31.2023

By Robert Martone Neurological conditions can release a torrent of new creativity in a few people as if opening some mysterious floodgate. Auras of migraine and epilepsy may have influenced a long list of artists, including Pablo Picasso, Vincent van Gogh, Edvard Munch, Giorgio de Chirico, Claude Monet and Georges Seurat. Traumatic brain injury (TBI) can result in original thinking and newfound artistic drive. Emergent creativity is also a rare feature of Parkinson’s disease. But this burst of creative ability is especially true of frontotemporal dementia (FTD). Although a few rare cases of FTD are linked to improvements in verbal creativity, such as greater poetic gifts and increased wordplay and punning, enhanced creativity in the visual arts is an especially notable feature of the condition. Fascinatingly, this burst of creativity indicates that the potential to create may rest dormant in some of us, only to be unleashed by a disease that also causes a loss of verbal abilities. The emergence of a vibrant creative spark in the face of devastating neurological disease speaks to the human brain’s remarkable potential and resilience. A new study published in JAMA Neurology examines the roots of this phenomenon and provides insight into a possible cause. As specific brain areas diminish in FTD, the researchers find, they release their inhibition, or control, of other regions that support artistic expression. Frontotemporal dementia is relatively rare—affecting about 60,000 people in the U. S.—and distinct from the far more common Alzheimer’s disease, a form of dementia in which memory deficits predominate. FTD is named for the two brain regions that can degenerate in this disease, specifically the frontal and temporal lobes.

Keyword: Alzheimers; Attention
Link ID: 28797 - Posted: 05.27.2023

By Jennie Erin Smith José Echeverría spends restless days in a metal chair reinforced with boards and padded with a piece of foam that his mother, Nohora Vásquez, adjusts constantly for his comfort. The chair is coming loose and will soon fall apart. Huntington’s disease, which causes José to move his head and limbs uncontrollably, has already left one bed frame destroyed. At 42, he is still strong. José’s sister Nohora Esther Echeverría, 37, lives with her mother and brother. Just two years into her illness, her symptoms are milder than his, but she is afraid to walk around her town’s steep streets, knowing she could fall. A sign on the front door advertises rum for sale that does not exist. The family’s scarce resources now go to food — José and Nohora Esther must eat frequently or they will rapidly lose weight — and medical supplies, like a costly cream for Jose’s skin. Huntington’s is a hereditary neurodegenerative disease caused by excess repetitions of three building blocks of DNA — cytosine, adenine, and guanine — on a gene called huntingtin. The mutation results in a toxic version of a key brain protein, and a person’s age at the onset of symptoms relates, roughly, to the number of repetitions the person carries. Early symptoms can include mood disturbances — Ms. Vásquez remembers how her late husband had chased the children out of their beds, forcing her to sleep with them in the woods — and subtle involuntary movements, like the rotations of Nohora Esther’s delicate wrists. The disease is relatively rare, but in the late 1980s a Colombian neurologist, Jorge Daza, began observing a striking number of cases in the region where Ms. Vásquez lives, a cluster of seaside and mountain towns near Barranquilla. Around the same time, American scientists led by Nancy Wexler were working with an even larger family with Huntington’s in neighboring Venezuela, gathering and studying thousands of tissue samples from them to identify the genetic mutation responsible. © 2023 The New York Times Company

Keyword: Huntingtons; Genes & Behavior
Link ID: 28796 - Posted: 05.23.2023